The Street thinks Gilead is entering a period of anemic growth. A quick look at the biotech’s healthy free cash flows, though, shows why this top biotech could defy this pessimistic outlook.
The Street thinks Gilead is entering a period of anemic growth. A quick look at the biotech’s healthy free cash flows, though, shows why this top biotech could defy this pessimistic outlook.